

REMARKS

A Substitute Sequence Listing has been provided along with a Computer Readable Form of the Sequence Listing. The undersigned hereby states that the Paper Copy and the Computer Readable Form of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821, including 1.821(c) and 1.821(e) are identical. No new matter has been added by this substitution. Applicants include a copy of the Notice to Comply.

No fees are believed due with this paper, but the Commissioner is hereby authorized to charge any fees under 37 CFR § 1.17 which may be required to Account No. 19-0134, Novartis Corporation.

Favorable consideration of this application is respectfully requested.

Respectfully submitted,


Hesna J. Pfeiffer
Attorney for Applicants
Reg. No. 22,640

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6940
Date: June 18, 2002

21001 sequence submission

Enclosures: a CRF discette, substitute pages 37-111, Copy of CRF notice to comply